there is no tumor specific antigen (TSA) available for target, those antigens chosen as target, they also expressed at normal cells, which inevitably causes various adverse reactions, in this article, tumor lysis syndrome (TLS) is briefly reviewed. Editorial In 1975, Monoclonal antibody (mAb) technique was created by Georges Köhler, César Milstein, and Niels Kaj Jerne by using mouse x mouse hybridoma, they shared the Nobel Prize in Physiology or Medicine in 1984 for the discovery. 8 years later, in 1992 FDA approved first therapeutic mAb Muromonab-CD3 (trade name Orthoclone OKT3) to reduce acute rejection in patients with organ transplants, since then, as of May 31, 2017, FDA has approved 70 therapeutic mAbs [1-3]. Among them 28 were approved for treatment of cancers (Table 1) [4-31]. These therapeutic mAb targets at components expressed on cancer cell, possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC), antibody-dependent cell mediated cytotoxicity (ADCC), induced apoptosis, cancer cell growth inhibition, direct cytoxicities, and conjugates indirect effect resulting cancer cell death (radiation or internalized derives). Unfortunately, so far Table 1: Monoclonal Antibodies for Cancer Therapy Approved By FDA.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.